Insight Molecular Diagnostics Inc. — Director's Dealing 2022

Jun 13, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2022-06-01

Reporting Person: John Anish M. (SVP, Finance, and Interim CFO)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$3.80	2031-09-13	Common Stock (125000)		Direct
Option to Purchase Common Stock	$1.15	2032-03-15	Common Stock (37500)		Direct
Option to Purchase Common Stock	$1.15	2032-03-15	Common Stock (37500)		Direct

Footnotes

F1: 25% of the options will become exercisable after one year of continuous employment from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continued employment on the applicable vesting dated.

F2: Options vest subject to the Issuer's achievement of pre-defined product and regulatory goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.